From 1 January 2021, Regulation (EU) 2020/878 came into force, amending Annex II of the Reach.
The main changes concern the presence of the new UFI code (Annex VIII of the CLP regulation), the modification of section 3 and section 9, the nanoforms and the inclusion of information relating to endocrine disruptors. Some section and subsection titles are also changed, as well as two new subsections.
Below we list the main news:
• UFI code
In section 1.1 of the safety data sheet, the UFI code (Unique Formula Identifier) must be reported in accordance with the procedures set out in Annex VIII of the CLP Regulation part A section 5.
• Section 3
As regards section 3, it will be necessary, with respect to the Regulation currently in force, to indicate the specific concentration limit, the M factor and the estimate of acute toxicity for the substances included in Annex VI of Reg. (EC) 1272/2008. Furthermore, if the substance is registered and refers to a nanoform, the characteristics of the particles that make up the nanoform must be indicated, as described in Annex VI of the REACH Regulation. The concentration limits for which a substance must be listed in section 3.2 will be updated and changed
• Section 9
A new and interesting modification will affect all the end-points of this section. For each of them, the required information, definitions, cases of applicability and non-applicability and in some cases the appropriate temperatures to be indicated in the SDS will be specified and described.
• Section 11
Information on adverse health effects caused by endocrine disrupting properties (where available) for substances identified as such if present in subsection 2.3 of the SDS shall be provided in subsection 11.2.
The new regulation applies from 1 January 2021, however the adaptation of the SDS to the new changes may take place with a transitional period that will end on 31 December 2022.